A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)

Key facts

Sponsor

Hoffmann-La Roche

Principal Investigator

Clinical Trials

Hoffmann-La Roche

Intervention

Atezolizumab(drug)

Enrollment

687 target

Eligibility

18 years · All sexes

Timeline

2023 – 2026

Study locations (30)

• Genesis Cancer Center, Hot Springs, Arkansas, United States
• UCSF Fresno at Community Cancer Institute, Clovis, California, United States
• City of Hope Cancer Center, Duarte, California, United States
• University of California San Diego Moores Cancer Center, La Jolla, California, United States
• University of Southern California, Los Angeles, California, United States
• Stanford Cancer Center, Palo Alto, California, United States
• Va Palo Alto Health Care System, Palo Alto, California, United States
• UCLA Cancer Center, Santa Monica, California, United States
• Hartford Healthcare Cancer Institute at Hartford Hospital, Hartford, Connecticut, United States
• MedStar Washington Hosp Center, Washington D.C., District of Columbia, United States
• Florida Cancer Specialists - Fort Myers (Broadway), Fort Myers, Florida, United States
• Miami VA Healthcare System, Miami, Florida, United States
• Florida Cancer Specialist, North Region, St. Petersburg, Florida, United States
• University of Illinois, Chicago, Illinois, United States
• Norton Cancer Institute - Audubon, Louisville, Kentucky, United States
• +15 more locations on ClinicalTrials.gov

Collaborators

Chugai Pharmaceutical

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Combined hepatocellular carcinoma and cholangiocarcinoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT06902246
  Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
  University of Miami
• RECRUITINGPHASE1NCT07419841
  A Phase 1 Study of the Safety and Tolerability of CTX-10726
  Compass Therapeutics
• RECRUITINGPHASE1NCT07493044
  An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular Carcinoma
  Guangzhou FineImmune Biotechnology Co., LTD.
• RECRUITINGPHASE2NCT07122089
  Evaluation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Carcinoma With Portal Vein Thrombosis
  Center Eugene Marquis
• RECRUITINGPHASE1, PHASE2NCT07482059
  A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma
  West China Hospital
• RECRUITINGPHASE2NCT06254248
  Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma
  Assistance Publique - Hôpitaux de Paris
• RECRUITINGNANCT07469319
  Biannual Screening for HCC Offered to Patients With Cirrhosis. Introducing Surveillance for Hepatocellular Carcinoma (HCC) in the Central Denmark Region Using Ultrasound and Alpha-Fetoprotein to Reduce HCC-Related Mortality in Patients With Compensated Non-Viral Cirrhosis
  University of Aarhus
• RECRUITINGEARLY PHASE1NCT07242417
  TC-G203 for Patients With GPC3-Positive Advanced Solid Tumors
  Beijing GoBroad Hospital

See all trials for Combined hepatocellular carcinoma and cholangiocarcinoma →